At a town hall meeting last night, presidential candidate Hillary Clinton vowed to "go after," Valeant Pharmaceuticals, after a woman handed her a note about her diabetes medication. The note said ...

Bausch Health Cos. convinced a federal court to dismiss, for now, allegations that executives misled investors about the spin-off of Bausch + Lomb, and other corporate liabilities.

The FDA has finally approved Valeant’s eye drug Vyzulta after the company finally satisfied the regulator’s concerns over its manufacturing facility in Florida. The Quebec-based company’s ...

Valeant Pharmaceuticals International, Inc. is a multinational specialty pharmaceutical company that develops, manufactures, and markets a range of branded and generic pharmaceuticals, over-the ...

a first-in-class potassium-channel opener developed by Valeant Pharmaceuticals for the treatment of epilepsy. GSK will also gain the rights to Valeant's back-up compounds that target potassium ...

Valeant Pharmaceuticals' outgoing CEO Mike Pearson, the company's former interim CEO Howard Schiller, and board member and hedge fund billionaire Bill Ackman, are all testifying before the US ...

On Wednesday embattled drug maker Valeant will present its guidance for 2016 in a four-hour Investor Day conference call that starts at 8:00 am EST. It will have a lot of explaining to do ...

Ask about health care at a summer cookout, and you’ll likely get an earful about how drug corporations are gouging us, leaving many families to choose between buying medications or putting ...

It was up nearly 41 percent last year and another 88 percent this year. It looks like the rally in Valeant Pharmaceuticals’ stock has been short circuited — at least for now. Shares of the ...